Design and Evaluation of <sup>223</sup>Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

Design and Evaluation of <sup>223</sup>Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy—Part II. Toxicity, Pharmacokinetics and Biodistribution

Metastatic castration-resistant prostate cancer (mCRPC) is a progressive and incurable disease with poor prognosis for patients. Despite introduction of novel therapies, the mortality rate remains high. An attractive alternative for extension of the life of mCRPC patients is PSMA-based targeted radi...

Full description

Bibliographic Details
Main Authors: Anna Lankoff, Malwina Czerwińska, Rafał Walczak, Urszula Karczmarczyk, Kamil Tomczyk, Kamil Brzóska, Giulio Fracasso, Piotr Garnuszek, Renata Mikołajczak, Marcin Kruszewski
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:International Journal of Molecular Sciences
Subjects:
PSMA-targeted radioligand therapy
prostate cancer
radium-223
D2B antibodies
zeolite nanoparticles
toxicity
Online Access:https://www.mdpi.com/1422-0067/22/11/5702

Internet

https://www.mdpi.com/1422-0067/22/11/5702

Similar Items